Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evoq Remedies's EBITDA for the
six
months ended in Mar. 2026 was ₹-3.1 Mil. Evoq Remedies's Revenue for the
six
months ended in Mar. 2026 was ₹0.0 Mil. Therefore, Evoq Remedies's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Evoq Remedies EBITDA Margin % Related Terms
Evoq Remedies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Evoq Remedies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543500 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Evoq Remedies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoq Remedies (BOM:543500) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evoq Remedies and its competitors. According to the industry distribution chart, Evoq Remedies ranks #101 out of 118 companies in the Medical Distribution industry, placing it in the top 85.6%.
Is Evoq Remedies' EBITDA Margin % too high?
Evoq Remedies' current EBITDA Margin % is 0.00%. Based on the distribution chart, Evoq Remedies ranks #101 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Evoq Remedies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #101 out of 118 companies for EBITDA Margin %. This places Evoq Remedies in the lower half of its industry. The industry median EBITDA Margin % is 4.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.24, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.94, compared to a current price of ₹1.75 — trading 86.5% below its estimated fair value. The current EBITDA Margin % is 0.00%. Evoq Remedies' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.75 is trading 86.5% below its estimated GF Value™ of ₹12.94.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
EBITDA Margin %: 0.00%
GF Value™: ₹12.94 vs. price of ₹1.75 (86.5% below fair value)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
60GF Score
Get the complete analysis for BOM:543500
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
